PROTHENA CORP PUBLIC LTD CO — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Prothena reported Q2 2026 net loss of $18.6M (vs. $125.8M loss in Q2 2025) and H1 2026 net income of $14.1M (vs. $186M loss in H1 2025), driven primarily by a $50M milestone payment from Novo Nordisk for coramitug Phase 3 progress. Cash position was $289.1M as of June 30, 2026; company repurchased 2.24M shares ($22.3M) in H1 2026 under a $100M program expiring December 31, 2026, and updated year-end cash guidance to $259M (midpoint). R&D expenses fell 76% YoY to $8.8M in Q2, reflecting lower clinical trial and personnel costs following prior restructuring.
Why this rating
Milestone and restructuring gains mask underlying burn; $259M cash midpoint adequate for 18–23 months at $18–23M annual net burn. Share repurchases ($12M through July 30) reduce runway. Partnered programs offer upside, but company remains pre-revenue biotech dependent on partner clinical success and future milestones.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.